0001104659-23-008584.txt : 20230131
0001104659-23-008584.hdr.sgml : 20230131
20230131160430
ACCESSION NUMBER: 0001104659-23-008584
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230127
FILED AS OF DATE: 20230131
DATE AS OF CHANGE: 20230131
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ford David A
CENTRAL INDEX KEY: 0001705295
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35668
FILM NUMBER: 23572543
MAIL ADDRESS:
STREET 1: 7 OAKRIDGE ROAD
CITY: ANNANDALE
STATE: NJ
ZIP: 08801
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INTERCEPT PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001270073
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 223868459
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 305 MADISON AVENUE
CITY: MORRISTOWN
STATE: NJ
ZIP: 07960
BUSINESS PHONE: 646-747-1000
MAIL ADDRESS:
STREET 1: 305 MADISON AVENUE
CITY: MORRISTOWN
STATE: NJ
ZIP: 07960
FORMER COMPANY:
FORMER CONFORMED NAME: INTERCEPT PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20031113
4
1
tm234878-3_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2023-01-27
0
0001270073
INTERCEPT PHARMACEUTICALS, INC.
ICPT
0001705295
Ford David A
C/O INTERCEPT PHARMACEUTICALS, INC.
305 MADISON AVENUE
MORRISTOWN
NJ
07960
0
1
0
0
Chief Human Resources Officer
Common Stock
2023-01-27
4
A
0
9800
0
A
36438
D
Option to Purchase Common Stock
18.40
2023-01-27
4
A
0
16000
0
A
2033-01-27
Common Stock
16000
16000
D
Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2023.
The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2023.
/s/ Rocco Venezia, as attorney-in-fact
2023-01-31